UA116773C2 - Способи отримання (s)-1-(3-етокси-4-метоксифеніл)-2-метансульфонілетиламіну - Google Patents

Способи отримання (s)-1-(3-етокси-4-метоксифеніл)-2-метансульфонілетиламіну

Info

Publication number
UA116773C2
UA116773C2 UAA201410289A UAA201410289A UA116773C2 UA 116773 C2 UA116773 C2 UA 116773C2 UA A201410289 A UAA201410289 A UA A201410289A UA A201410289 A UAA201410289 A UA A201410289A UA 116773 C2 UA116773 C2 UA 116773C2
Authority
UA
Ukraine
Prior art keywords
ethoxy
methods
metoxyphenil
methansulphonylethylamine
obtaining
Prior art date
Application number
UAA201410289A
Other languages
English (en)
Inventor
Джасті Венкатесваралу
Чіннапіллаі Раджендіран
Налламадді Равікумар Редді
Терренс Джозеф Конноллі
Алєксандер Л. Рачелмен
Джеффрі Еккерт
Ентоні Джозеф Френк
Original Assignee
Селджин Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47755073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA116773(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Селджин Корпорейшн filed Critical Селджин Корпорейшн
Publication of UA116773C2 publication Critical patent/UA116773C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

У даному винаході надані нові способи отримання проміжних аміносульфонових сполук для синтезу 2-[1-(3-етокси-4-метоксифеніл)-2-метилсульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону, який застосовується для попередження або лікування захворювань або станів, пов'язаних із аномально високим рівнем або активністю ФНП-(. Крім того, у даному винаході надані способи комерційного виробництва (S)-1-(3-етокси-4-метоксифеніл)-2-метансульфонілетиламіну.
UAA201410289A 2012-02-21 2013-02-20 Способи отримання (s)-1-(3-етокси-4-метоксифеніл)-2-метансульфонілетиламіну UA116773C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601226P 2012-02-21 2012-02-21
PCT/US2013/026780 WO2013126360A2 (en) 2012-02-21 2013-02-20 Processes for the preparation of (s)-1-(3-ethoxy-4methoxyphenyl)-2-methanesulfonylethylamine

Publications (1)

Publication Number Publication Date
UA116773C2 true UA116773C2 (uk) 2018-05-10

Family

ID=47755073

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201410289A UA116773C2 (uk) 2012-02-21 2013-02-20 Способи отримання (s)-1-(3-етокси-4-метоксифеніл)-2-метансульфонілетиламіну

Country Status (36)

Country Link
US (3) US9187417B2 (uk)
EP (4) EP2817288B1 (uk)
JP (1) JP2015509496A (uk)
KR (1) KR101993248B1 (uk)
CN (3) CN107033042A (uk)
AR (2) AR090100A1 (uk)
AU (1) AU2013203283B2 (uk)
BR (3) BR122021020040B1 (uk)
CA (1) CA2864517A1 (uk)
CO (1) CO7061071A2 (uk)
CR (1) CR20140395A (uk)
CY (2) CY1121833T1 (uk)
DK (2) DK3312156T3 (uk)
ES (4) ES2735801T3 (uk)
HR (2) HRP20191249T1 (uk)
HU (2) HUE048412T2 (uk)
IL (3) IL234135A (uk)
IN (1) IN2014DN06740A (uk)
LT (2) LT3312156T (uk)
MX (2) MX344190B (uk)
MY (1) MY168296A (uk)
NI (1) NI201400093A (uk)
NZ (1) NZ628028A (uk)
PH (1) PH12014501865A1 (uk)
PL (2) PL3312156T3 (uk)
PT (2) PT3378850T (uk)
RS (2) RS60036B1 (uk)
RU (1) RU2632875C2 (uk)
SG (1) SG11201405035XA (uk)
SI (2) SI3312156T1 (uk)
SM (2) SMT201900397T1 (uk)
TR (1) TR201910430T4 (uk)
TW (1) TW201336815A (uk)
UA (1) UA116773C2 (uk)
WO (1) WO2013126360A2 (uk)
ZA (1) ZA201405892B (uk)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
EP3010490A1 (en) 2013-06-17 2016-04-27 Celgene Corporation Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
IN2014MU01283A (uk) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
EP3143004B1 (en) 2014-05-11 2020-09-02 Mapi Pharma Limited Amorphous form of apremilast
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
CN105622380B (zh) * 2014-10-29 2020-06-30 南京安源生物医药科技有限公司 一种阿普斯特的制备方法及其中间体
CN104447445B (zh) * 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
CN104761474B (zh) * 2015-03-11 2016-11-30 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成方法
CN104744323B (zh) * 2015-03-11 2016-08-31 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成工艺
CN104803897A (zh) * 2015-04-23 2015-07-29 中山奕安泰医药科技有限公司 一种阿普斯特中间体的合成工艺
WO2016174685A1 (en) 2015-04-27 2016-11-03 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
MX2017016054A (es) * 2015-06-09 2018-04-11 Dr Reddys Laboratories Ltd Proceso para la preparacion de apremilast y sus intermedios.
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
WO2017059040A1 (en) 2015-09-29 2017-04-06 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
WO2017085568A1 (en) * 2015-11-19 2017-05-26 Alembic Pharmaceuticals Limited An improved process and novel polymorphic form of apremilast
CN105330586B (zh) * 2015-11-27 2017-12-22 东华大学 一种阿普斯特的制备方法
CN105461602B (zh) * 2015-11-27 2018-01-02 东华大学 手性S或R‑3‑乙氧基‑4‑甲氧基‑α‑[(甲磺酰基)甲基]苯甲醇的制备方法
WO2017094031A2 (en) * 2015-12-04 2017-06-08 Sun Pharmaceutical Industries Limited Novel process for preparation of apremilast
CN106866475B (zh) * 2015-12-11 2018-03-30 北大方正集团有限公司 一种阿普斯特中间体及其制备方法
US10774041B2 (en) 2016-04-15 2020-09-15 Davuluri Ramamohan Rao Process for the preparation of apremilast
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN106543050B (zh) * 2016-09-28 2018-04-10 中南大学湘雅医院 一种阿普斯特中间体的合成工艺
WO2018061034A1 (en) * 2016-09-30 2018-04-05 Sun Pharmaceutical Industries Limited Novel process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine
WO2018086762A1 (de) 2016-11-10 2018-05-17 Sms Group Gmbh VERFAHREN ZUM HERSTELLEN EINES METALLISCHEN BANDES IN EINER GIEßWALZANLAGE
CN107445875A (zh) * 2017-03-22 2017-12-08 陕西科技大学 一种用于制备阿普斯特的高纯度中间体的手性拆分方法
WO2018184933A1 (en) 2017-04-04 2018-10-11 Quimica Sintetica, S. A. Racemic beta-aminosulfone compounds
HRP20201376T1 (hr) 2017-04-04 2020-12-11 Quimica Sintetica, S.A. Rezolucija racemičnih beta-aminosulfonskih spojeva
CN108008035B (zh) * 2017-11-23 2020-07-07 中山奕安泰医药科技有限公司 3-乙氧基-4-甲氧基苯甲醛纯度的检测方法
CN107966509B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种(s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN107976501B (zh) * 2017-11-23 2020-08-25 中山奕安泰医药科技有限公司 一种1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN107827722B (zh) * 2017-11-23 2021-02-19 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲醛的合成方法
CN107941945B (zh) * 2017-11-23 2020-12-22 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲腈的检测方法
CN108084066A (zh) * 2017-12-12 2018-05-29 中山大学 一种阿普斯特及对映异构体的合成方法
JP6673614B1 (ja) * 2018-10-16 2020-03-25 東芝エレベータ株式会社 防音装置
CN113896674B (zh) * 2021-09-01 2023-10-27 深圳华中科技大学研究院 一种阿普斯特的合成方法
EP4455148A4 (en) 2021-12-21 2026-03-04 Ganzhou Hemay Pharmaceutical Co Ltd Preparation for thiophene derivative
CN115850129B (zh) * 2023-02-28 2023-05-16 凯莱英生命科学技术(天津)有限公司 （s）-1-(3-乙氧基-4-甲氧基苯基)-2-（甲磺酰基）乙胺的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1261455A (en) * 1969-03-06 1972-01-26 Burroughs Wellcome Co Improvements in or relating to substituted acrylonitriles
US3878252A (en) * 1970-09-24 1975-04-15 Burroughs Wellcome Co Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide
DE2051871A1 (en) * 1969-05-16 1971-11-18 The Wellcome Foundation Ltd., London Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents
PL329070A1 (en) 1996-03-22 1999-03-15 Du Pont Pharm Co Novel dissymetrical synthesis of r-alpha-propylpiperonylamine and its analoques
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
DE60330187D1 (de) 2002-12-30 2009-12-31 Celgene Corp Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
MX2010007768A (es) * 2008-01-25 2010-11-09 High Point Pharmaceuticals Llc Compuestos triciclicos como moduladores de la sintesis del factor de necrosis tumoral alfa y como inhibidores de la fosfodiesterasa 4.
HRP20130356T1 (en) * 2008-09-10 2013-05-31 Celgene Corporation Processes for the preparation of aminosulfone compounds
EP3090999A1 (en) * 2009-06-18 2016-11-09 Concert Pharmaceuticals Inc. Deuterated isoindoline-1, 3-dione derivatives as pde4 and tnf-alpha inhibitors
JP5753177B2 (ja) 2009-10-09 2015-07-22 セルジーン コーポレイション ２−（１−フェニルエチル）イソインドリン−１−オン化合物を調製する方法
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds

Also Published As

Publication number Publication date
ES2971710T3 (es) 2024-06-06
CO7061071A2 (es) 2014-09-19
IL234135A (en) 2017-06-29
CN112812044B (zh) 2023-05-30
SMT202000107T1 (it) 2020-03-13
DK3378850T3 (da) 2020-03-16
PL3312156T3 (pl) 2019-10-31
EP3378850B8 (en) 2020-03-04
TW201336815A (zh) 2013-09-16
PT3378850T (pt) 2020-03-06
EP2817288A2 (en) 2014-12-31
HK1205501A1 (en) 2015-12-18
NZ628028A (en) 2016-03-31
LT3378850T (lt) 2020-04-10
MX344190B (es) 2016-12-08
EP2817288B1 (en) 2018-05-30
ES2675168T3 (es) 2018-07-09
MY168296A (en) 2018-10-23
NI201400093A (es) 2016-11-30
CY1122799T1 (el) 2021-05-05
SMT201900397T1 (it) 2019-09-09
BR122021020046B1 (pt) 2022-05-31
US9586897B2 (en) 2017-03-07
EP3702347B1 (en) 2023-11-08
US20160031808A1 (en) 2016-02-04
BR122021020040B1 (pt) 2022-05-31
KR20140126389A (ko) 2014-10-30
AR090100A1 (es) 2014-10-22
TR201910430T4 (tr) 2019-08-21
LT3312156T (lt) 2019-08-12
MX2014010002A (es) 2014-09-08
MX350731B (es) 2017-09-15
EP3378850B1 (en) 2020-01-08
CN104245668A (zh) 2014-12-24
EP3702347A1 (en) 2020-09-02
WO2013126360A2 (en) 2013-08-29
AU2013203283A1 (en) 2013-09-05
US9688623B2 (en) 2017-06-27
SI3312156T1 (sl) 2019-09-30
PH12014501865B1 (en) 2014-11-17
CY1121833T1 (el) 2020-10-14
IL273050A (en) 2020-04-30
KR101993248B1 (ko) 2019-06-26
HRP20191249T1 (hr) 2019-10-18
CN112812044A (zh) 2021-05-18
CN104245668B (zh) 2017-05-17
JP2015509496A (ja) 2015-03-30
RU2014138037A (ru) 2016-04-10
RU2632875C2 (ru) 2017-10-11
SI3378850T1 (sl) 2020-07-31
HUE044192T2 (hu) 2019-10-28
WO2013126360A3 (en) 2013-10-31
US9187417B2 (en) 2015-11-17
EP3312156A1 (en) 2018-04-25
DK3312156T3 (da) 2019-07-22
AU2013203283B2 (en) 2015-11-26
CA2864517A1 (en) 2013-08-29
SG11201405035XA (en) 2014-09-26
US20130217918A1 (en) 2013-08-22
IL252459B (en) 2020-03-31
BR112014020444B1 (pt) 2021-12-07
IL252459A0 (en) 2017-07-31
ZA201405892B (en) 2015-11-25
US20170129852A1 (en) 2017-05-11
PT3312156T (pt) 2019-07-19
IN2014DN06740A (uk) 2015-05-22
ES2773686T3 (es) 2020-07-14
CN107033042A (zh) 2017-08-11
RS59071B1 (sr) 2019-09-30
ES2735801T3 (es) 2019-12-20
HRP20200245T1 (hr) 2020-05-15
EP3312156B1 (en) 2019-06-05
HUE048412T2 (hu) 2020-07-28
PH12014501865A1 (en) 2014-11-17
BR112014020444A2 (pt) 2020-10-27
EP3378850A1 (en) 2018-09-26
AR117963A2 (es) 2021-09-08
RS60036B1 (sr) 2020-04-30
PL3378850T3 (pl) 2020-07-27
CR20140395A (es) 2014-11-17

Similar Documents

Publication Publication Date Title
UA116773C2 (uk) Способи отримання (s)-1-(3-етокси-4-метоксифеніл)-2-метансульфонілетиламіну
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
NZ711896A (en) Compounds and methods for kinase modulation, and indications therefor
MX378512B (es) Composiciones de pirrolopirrol como activadores de piruvato cinasa (pkr).
EA201500362A1 (ru) Ингибиторы rho-киназы
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201391019A1 (ru) Соединения и способы для модуляции киназ, а также показания к их применению
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MX375902B (es) Inhibidores de serina/treonina cinasa.
UA117929C2 (uk) Сполуки піримідиндіону, спрямовані проти станів серцево-судинної системи
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
EA201692271A1 (ru) Терапевтически активные соединения и способы их применения
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
UA113750C2 (xx) Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
EA201490540A1 (ru) Соединения и композиции в качестве ингибиторов с-kit киназы
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
UA112795C2 (uk) Біциклічні піразинонові похідні
EA201590881A1 (ru) Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
EA201170672A1 (ru) Соединения, пригодные для лечения целлюлита